Any wrong or incomplete data? Any missing, misplaced, unlicensed picture? Please report any abuse, inaccuracy or lack of information to info@ticinoscienza.ch

1) Metabolic modulation of tumours with engineered bacteria for immunotherapy
Nature, ottobre 2021

2) Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis
Science, 8 ottobre 2021

3) Co-occurrence and mutual exclusivity: what cross-cancer mutation patterns can tell us
Trends in Cancer, 21 maggio 2021

4) Patient-derived xenografts and organoids model therapy response in prostate cancer
Nature Communications, 18 febbraio 2021

5) Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer
Nature Communications, 2 febbraio 2021

6) Circulating extracellular vesicles release oncogenic miR-424 in experimental models and patients with aggressive prostate cancer
Communications Biology, 26 gennaio 2021

7) Loss and revival of androgen receptor signaling in advanced prostate cancer
Oncogene, 8 gennaio 2021

8) STAT3-dependent analysis reveals PDK4 as independent predictor of recurrence in prostate cancer.
molecular systems biology, https://www.embopress.org/doi/full/10.15252/msb.20199247

9) CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo.
The Journal of Clinical Investigation, https://www.jci.org/articles/view/131133

10) De Novo Variants in SPOP Cause Two Clinically Distinct Neurodevelopmental Disorders.
American Journal of Human Genetics, https://www.cell.com/ajhg/fulltext/S0002-9297(20)30043-4

11) TIP5 primes prostate luminal cells for the oncogenic transformation mediated by PTEN-loss.
Proceedings of the National Academy of Sciences of the United States of America, https://www.pnas.org/content/early/2020/02/04/1911673117
Jean Philippe Theurillat
is currently collaborating with
Istituto Oncologico di Ricerca (IOR) (Rif. IOR)
Via Francesco Chiesa 5
6500 Bellinzona
Jean Philippe Theurillat
on behalf of
Istituto Oncologico di Ricerca (IOR) USI (Rif. IOR)
is currently participating in the Research Group
Functional Cancer Genomics
as Group Leader [Rif. 55110]